C

한국파마

032300KOSDAQ

49.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Rose 9.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Hanok Pharma focuses on developing and selling prescription drugs for various disease areas such as the central nervous system and circulatory system through its own R&D. It expands its research in biopharmaceuticals and improved drugs via research centers in Daegu and Uijeongbu. Additionally, the company engages in CMO business, producing solid dosage forms and topical solutions, and is expanding its global market through exports and licensing-out deals.

Number of Employees

284people

Average Salary

67.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
1.26Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE
-3.77Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
1.87Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.0 / 10 points
Revenue Growth Rate
1.0 / 3

Avg ▲2.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼58.8% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 0.6% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (15%, downtrend)

Current 7,920Won52-week high 14,09052-week low 6,800
1-month return5.0Point

1m +9.24% (rising)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 1Neutral 0Negative 0
  • Positive주요사항보고서(자기주식취득신탁계약체결결정)2026-10-02